Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer
A Phase 1 Study Of Paclitaxel In Combination With SU011248 For Patients With Breast Cancer As First-Line Treatment In The Advanced Disease Setting
Sponsor: Pfizer
Listed as NCT00174434, this PHASE1 trial focuses on Breast Neoplasms and remains completed. Sponsored by Pfizer, it has been updated 6 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
Sep 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .